This webinar has been organised and funded by GSK UK. See bottom of page for full disclaimer.

*This GSK webinar contains promotional content

Incruse▼Ellipta (umeclidinium bromide): prescribing information
Anoro▼Ellipta (umeclidinium/vilanterol): prescribing information
Relvar Ellipta (fluticasone furoate/vilanterol): prescribing information
Trelegy▼Ellipta (fluticasone furoate/umeclidinium/vilanterol): prescribing information

Register now to GSKpro to access future webinars with medical experts and more.

Watch presentation from expert speakers:  

frances barrett

Frances Barrett
Practice Nurse specialising in respiratory care

jennifer quint

Dr Jennifer Quint
Consultant Respiratory Physician


sue collier

Dr Sue Collier

UK National Physician Lead, GSK Respiratory


Learning objectives of this webinar: 

  • Discussion of tools to support the confirmation of COPD diagnosis
  • Review the impact of symptoms and exacerbations on patients with COPD
  • Explore the role of LAMA/LABA and ICS/LABA/LAMA maintenance medication in the treatment of COPD through problem-based case studies.

COPD=chronic obstructive pulmonary disease; ICS=inhaled corticosteroids; LABA=long-acting beta agonist; LAMA=long-acting muscarinic antagonist.

This webinar has been organised and funded by GSK UK. GSK UK has carried out full medical approval on all material to ensure compliance with regulations. Guidelines has had no involvement in the development of this webinar. The views and opinions of the speakers are not necessarily those of Guidelines, its publisher, advisers, or advertisers.

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.


Date of preparation: April 2020